The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Phase III EF-14 Trial Shows Tumor Treating Fields Improve OS in Brain Cancer

Roger Stupp, MD
Published Online: 3:01 PM, Sat November 19, 2016

Roger Stupp, MD, professor of oncology, University of Zurich, discusses the EF-14 trial which compared standard of care for glioblastoma plus or minus tumor treating fields with Optune. Median overall survival was 20.8 months for temozolomide plus Optune versus 16.0 months for temozolomide-alone (HR, 0.65; 95% CI, 0.54-0.79; P = .0006).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.